These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3260158)

  • 1. In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model.
    Hoffmann T; Böttger EC; Baum HP; Messner M; Hadding U; Bitter-Suermann D
    Clin Exp Immunol; 1988 Mar; 71(3):486-92. PubMed ID: 3260158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.
    Huey R; Bloor CM; Kawahara MS; Hugli TE
    Am J Pathol; 1983 Jul; 112(1):48-60. PubMed ID: 6859228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary injury induced by C3a and C5a anaphylatoxins.
    Stimler NP; Hugli TE; Bloor CM
    Am J Pathol; 1980 Aug; 100(2):327-48. PubMed ID: 6967702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a 72-77.
    Hartung HP; Bitter-Suermann D; Hadding U
    J Immunol; 1983 Mar; 130(3):1345-9. PubMed ID: 6600482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo.
    DiScipio RG; Daffern PJ; Jagels MA; Broide DH; Sriramarao P
    J Immunol; 1999 Jan; 162(2):1127-36. PubMed ID: 9916743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins.
    Chenoweth DE; Cooper SW; Hugli TE; Stewart RW; Blackstone EH; Kirklin JW
    N Engl J Med; 1981 Feb; 304(9):497-503. PubMed ID: 7453783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C3a induced activation and stimulus specific reversible desensitization of guinea pig platelets.
    Zanker B; Rasokat H; Hadding U; Bitter-Suermann D
    Agents Actions Suppl; 1982; 11():147-57. PubMed ID: 6983827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the third complement component (C3) and C3a generation in cardiac anaphylaxis: histamine release and associated inotropic and chronotropic effects.
    del Balzo U; Polley MJ; Levi R
    J Pharmacol Exp Ther; 1988 Sep; 246(3):911-6. PubMed ID: 2458450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells.
    Cecic I; Sun J; Korbelik M
    Photochem Photobiol; 2006; 82(2):558-62. PubMed ID: 16613513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
    Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
    Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human C5a des Arg increases vascular permeability.
    José PJ; Forrest MJ; Williams TJ
    J Immunol; 1981 Dec; 127(6):2376-80. PubMed ID: 6170701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement factors C3a and C5a have distinct hemodynamic effects in the rat.
    Proctor LM; Moore TA; Monk PN; Sanderson SD; Taylor SM; Woodruff TM
    Int Immunopharmacol; 2009 Jun; 9(6):800-6. PubMed ID: 19285573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation, purification and functional characterization of three C3a anaphylatoxins in rainbow trout: role in leukocyte chemotaxis and respiratory burst.
    Rotllant J; Parra D; Peters R; Boshra H; Sunyer JO
    Dev Comp Immunol; 2004 Jun; 28(7-8):815-28. PubMed ID: 15043949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microvascular effects of anaphylatoxins C3a and C5a.
    Björk J; Hugli TE; Smedegård G
    J Immunol; 1985 Feb; 134(2):1115-9. PubMed ID: 3871207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody.
    Burger R; Bader A; Kirschfink M; Rother U; Schrod L; Wörner I; Zilow G
    Clin Exp Immunol; 1987 Jun; 68(3):703-11. PubMed ID: 3498585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of C3a activity: internalization of the human C3a receptor and its inhibition by C5a.
    Settmacher B; Bock D; Saad H; Gärtner S; Rheinheimer C; Köhl J; Bautsch W; Klos A
    J Immunol; 1999 Jun; 162(12):7409-16. PubMed ID: 10358194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a.
    Reed SL; Ember JA; Herdman DS; DiScipio RG; Hugli TE; Gigli I
    J Immunol; 1995 Jul; 155(1):266-74. PubMed ID: 7602103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demonstration of a specific C3a receptor on guinea pig platelets.
    Fukuoka Y; Hugli TE
    J Immunol; 1988 May; 140(10):3496-501. PubMed ID: 3283237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylatoxins inhibit C2 production.
    Lappin D; Damerau B; Whaley K
    Clin Exp Immunol; 1983 Nov; 54(2):455-60. PubMed ID: 6317240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth.
    Coulthard LG; Woodruff TM
    J Immunol; 2015 Apr; 194(8):3542-8. PubMed ID: 25848071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.